<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Acad Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">J. Am. Acad. Dermatol</journal-id><journal-title-group><journal-title>Journal of the American Academy of Dermatology</journal-title></journal-title-group><issn pub-type="ppub">0190-9622</issn><issn pub-type="epub">1097-6787</issn><publisher><publisher-name>by the American Academy of Dermatology, Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7303642</article-id><article-id pub-id-type="publisher-id">S0190-9622(20)31149-X</article-id><article-id pub-id-type="doi">10.1016/j.jaad.2020.06.051</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Zahedi Niaki</surname><given-names>Omid</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Anadkat</surname><given-names>Milan J.</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Chen</surname><given-names>Steven T.</given-names></name><degrees>MD, MPH, MS-HPEd</degrees><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Fox</surname><given-names>Lindy P.</given-names></name><degrees>MD</degrees><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Harp</surname><given-names>Joanna</given-names></name><degrees>MD</degrees><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Micheletti</surname><given-names>Robert G.</given-names></name><degrees>MD</degrees><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Nambudiri</surname><given-names>Vinod E.</given-names></name><degrees>MD MBA</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Pasieka</surname><given-names>Helena B.</given-names></name><degrees>MD MS</degrees><xref rid="aff8" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au9"><name><surname>Shinohara</surname><given-names>Michi M.</given-names></name><degrees>MD</degrees><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au10"><name><surname>Rosenbach</surname><given-names>Misha</given-names></name><degrees>MD</degrees><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au11"><name><surname>Merola</surname><given-names>Joseph F.</given-names></name><degrees>MD, MMSc</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff10" ref-type="aff">j</xref></contrib><aff id="aff1"><label>a</label>Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts</aff><aff id="aff2"><label>b</label>Division of Dermatology, Washington University in St. Louis School of Medicine, St Louis, Missouri</aff><aff id="aff3"><label>c</label>Department of Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts</aff><aff id="aff4"><label>d</label>Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts</aff><aff id="aff5"><label>e</label>Department of Dermatology, University of California, San Francisco, California</aff><aff id="aff6"><label>f</label>Department of Dermatology, Weill Cornell Medicine, New York, New York</aff><aff id="aff7"><label>g</label>Departments of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania</aff><aff id="aff8"><label>h</label>Department of Dermatology, Georgetown University School of Medicine, Medstar Washington Hospital Center, Washington, DC</aff><aff id="aff9"><label>i</label>Division of Dermatology, Department of Medicine, University of Washington, Seattle, Washington</aff><aff id="aff10"><label>j</label>Division of Rheumatology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Correspondence to: Omid Zahedi Niaki, MD, 41 Avenue Louis Pasteur, 319, Boston, MA 02115.</corresp></author-notes><pub-date pub-type="pmc-release"><day>19</day><month>6</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>10</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>19</day><month>6</month><year>2020</year></pub-date><volume>83</volume><issue>4</issue><fpage>1150</fpage><lpage>1159</lpage><history><date date-type="accepted"><day>10</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the American Academy of Dermatology, Inc.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>American Academy of Dermatology, Inc.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0010"><p>Dermatologists treating immune-mediated skin disease must now contend with the uncertainties associated with immunosuppressive use in the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Although the risk of infection with many commonly used immunosuppressive agents remains low, direct data evaluating the safety of such agents in coronavirus disease 2019 (COVID-19) are scarce. This article reviews and offers guidance based on currently available safety data and the most recent COVID-19 outcome data in patients with immune-mediated dermatologic disease. The interdisciplinary panel of experts emphasizes a stepwise, shared decision-making approach in the management of immunosuppressive therapy. The goal of this article is to help providers minimize the risk of disease flares while simultaneously minimizing the risk of iatrogenic harm during an evolving pandemic.</p></abstract><kwd-group id="kwrds0010"><title>Key words</title><kwd>autoimmune disease</kwd><kwd>COVID-19</kwd><kwd>dermatology-rheumatology</kwd><kwd>immunosuppression</kwd><kwd>immunosuppressive therapy</kwd><kwd>medical dermatology</kwd><kwd>SARS-CoV-2</kwd></kwd-group><kwd-group id="kwrds0015"><title>Abbreviations used</title><kwd>CI, confidence interval</kwd><kwd>COVID-19, coronavirus disease 2019</kwd><kwd>IL, interleukin</kwd><kwd>MERS, Middle East respiratory syndrome</kwd><kwd>OR, odds ratio</kwd><kwd>RR, relative risk</kwd><kwd>SARS, severe acute respiratory syndrome</kwd><kwd>SARS-CoV-2, severe acute respiratory syndrome coronavirus 2</kwd><kwd>TNF, tumor necrosis factor</kwd><kwd>URI, upper respiratory tract</kwd><kwd>VTE, venous thromboembolism</kwd></kwd-group></article-meta></front><body><p id="p0010">
<boxed-text id="dtbox1"><caption><title>Capsule Summary</title></caption><p id="p0015">
<list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0020">This article adds to the limited literature on coronavirus disease 2019 (COVID-19) and immunosuppression. It provides expert opinion based on existing drug safety data and recent COVID-19 outcome data in patients with immune-mediated dermatologic disorders.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0025">The goal is to facilitate management of immunosuppressive drugs and minimize potential for harm in this patient population.</p></list-item></list>
</p></boxed-text>
</p><p id="p0030">In the context of the current coronavirus disease&#x000a0;2019 (COVID-19) pandemic, physicians treating patients with immune-mediated dermatologic diseases are tasked with challenging decisions when initiating immunosuppressive therapy or altering the existing regimens of their patients. This article will examine relevant systemic drug safety data obtained from clinical trials, registries, and cohort studies across disciplines to provide expert-derived guidance in the face of much uncertainty.</p><sec id="sec1"><title>Baseline risk in immune-mediated dermatologic disorders</title><p id="p0035">Evaluating the baseline infection risk of patients is&#x000a0;an important aspect of risk stratification. Several immune-mediated conditions, such as psoriasis and lupus, are associated with increased infection risk irrespective of exposure to immunomodulatory agents.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref>
<sup>,</sup>
<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Many of these conditions are further associated with comorbidities known to predict poor outcomes in COVID-19 infection (eg, diabetes and obesity in patients with psoriasis, asthma in patients with atopic dermatitis, and interstitial lung disease with connective tissue disorders).<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Each patient presents a unique set of variables that dictate the approach to their therapy plan. A summary of these considerations is found in <xref rid="tbl1" ref-type="table">Table I</xref>
.<table-wrap position="float" id="tbl1"><label>Table I</label><caption><p>Summary of key considerations in the shared decision-making process concerning immunosuppressive and immunomodulatory therapy during the coronavirus disease 2019 pandemic</p></caption><table frame="hsides" rules="groups"><tbody><tr><td><list list-type="simple" id="olist0010"><list-item id="o0010"><label>1.</label><p id="p0210">The severity of the underlying disease, with special consideration given to a history of flares with medication changes and potential need for emergency care.</p></list-item><list-item id="o0015"><label>2.</label><p id="p0215">The patient's underlying risk factors (eg, comorbidities).</p></list-item><list-item id="o0020"><label>3.</label><p id="p0220">Contextual factors impacting patient risk (eg, high-risk occupation, caregiver roles, at-risk individuals in the home or work environment, etc).</p></list-item><list-item id="o0025"><label>4.</label><p id="p0225">The patient's preferences and level of risk tolerance.</p></list-item><list-item id="o0030"><label>5.</label><p id="p0230">The level of exposure to health care settings dictated by the need for monitoring laboratory tests or administration of the drug (eg, infusions), or both.</p></list-item><list-item id="o0035"><label>6.</label><p id="p0235">The relative level of immunosuppression attributed to a given therapy or combination of therapies based on available information.</p></list-item></list></td></tr></tbody></table></table-wrap></p></sec><sec id="sec2"><title>Learning from the past</title><p id="p0040">COVID-19 appears to follow a disease course similar to previous highly pathogenic coronavirus infections (ie, Middle East respiratory syndrome [MERS] and severe acute respiratory syndrome [SARS]), with up to 20% of hospitalized patients progressing to potentially fatal acute respiratory distress syndrome.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> Risk factors for poor outcomes during the SARS and MERS outbreaks included older age and the presence of comorbidities such as obesity, diabetes, heart disease, lung disease, and renal disease. Immunosuppression alone was not identified as a significant risk factor for primary infection or death,<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref>
<sup>,</sup>
<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> and several milder or attenuated cases of infection were reported in immunosuppressed populations.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref>
<sup>,</sup>
<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> Corroborating this, a National Institutes of Health-funded animal study showed that macaques immunosuppressed with cyclophosphamide had significantly lower rates of lung pathology despite active MERS-CoV infection.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> It has been hypothesized that severe pulmonary involvement is likely secondary to an excessive inflammatory response, characterized by macrophage hyperactivation and high levels of proinflammatory cytokines.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref>
</p><p id="p0045">It is thought that dampening the hyperinflammatory reaction outweighs the risk of temporary impairment in antiviral immunity. Numerous clinical trials are underway to examine the therapeutic potential of various immunosuppressive and immunomodulatory agents in the treatment of COVID-19 and the potential associated cytokine storm. Existing drug safety data and relevant trial data are presented below.</p></sec><sec id="sec3"><title>Data regarding infection risk and complications of immunosuppressive and immunomodulatory agents</title><sec id="sec3.1"><title>Glucocorticoids</title><p id="p0050">Evidence linking systemic corticosteroids to increased infection risk comes from a meta-analysis of 71 clinical trials, which found an increased overall rate of infection in patients receiving systemic corticosteroids (relative risk [RR], 1.6; 95% confidence interval [CI], 1.3-1.9).<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> The risk was dose-dependent and minimal with daily doses &#x0003c;10&#x000a0;mg.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref>
<sup>,</sup>
<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> Similarly, observational data from the large Corrona registry (Corrona, LLC, Waltham, MA) also found increased overall infection risk with prednisone &#x0003e;10&#x000a0;mg/d in patients with rheumatoid arthritis (incidence rate ratio, 1.30; 95% CI, 1.1-1.5).<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref>
</p><sec id="sec3.1.1"><title>Therapeutic potential in COVID-19</title><p id="p0055">Data evaluating the use of systemic corticosteroids in COVID-19 are limited. Recently, the preliminary results of a large randomized controlled trial (RCT) conducted in the United Kingdom revealed reduced 28-day mortality and hospital length of stay in oxygen requiring or ventilated patients treated with dexamethasone 6 mg daily for 10 days as compared with usual care.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> Conversely, data from the SARS and MERS epidemics are conflicting and many studies have revealed no mortality benefit, delayed viral clearance, and evidence for harm.<xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref> A similar lack of benefit and potential for harm has been noted in other viral pneumonias, including influenza and respiratory syncytial virus.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref>
<sup>,</sup>
<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref>
</p></sec><sec id="sec3.1.2"><title>Conclusions</title><p id="p0060">There is evidence for harm without a clear mortality benefit when systemic corticosteroids have been used to treat MERS and SARS-associated pneumonia. Existing safety data also indicates that daily doses of systemic corticosteroids &#x0003e;10 mg of prednisone equivalent are associated with an increased susceptibility to overall infection. Recently however, preliminary evidence from a large RCT suggests that the use of dexamethasone reduces mortality in hospitalized COVID-19 patients. Further data are needed to define the optimal use and potential complications of systemic corticosteroid use in the setting of COVID-19.</p></sec></sec><sec id="sec3.2"><title>Methotrexate</title><p id="p0065">In clinical trials, methotrexate increased infection risk in patients with rheumatoid arthritis (risk ratio, 1.25; 95% CI, 1.01-1.56), compared with placebo, but not in those with other immune-mediated conditions, including psoriasis, psoriatic arthritis, ankylosing spondylitis, and scleroderma.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> Robust data for adverse events related to methotrexate come from a recent clinical trial evaluating the efficacy of low-dose methotrexate for the treatment of atherosclerosis in patients with cardiovascular disease. Mild infections were slightly increased (hazard ratio, 1.15; 95% CI, 1.01-1.30), but there was no statistically significant increase in upper respiratory tract (URI) or influenza infections.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref>
</p><sec id="sec3.2.1"><title>Conclusions</title><p id="p0070">A modestly increased risk of infection associated with methotrexate has been suggested in some studies. Further data are needed to understand the impact of methotrexate on SARS-CoV-2 infection.</p></sec></sec><sec id="sec3.3"><title>Antimalarial drugs</title><p id="p0075">When used for their immunomodulatory properties, antimalarials have not been associated with infectious complications in systemic autoimmune disease,<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref>
<sup>,</sup>
<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> and some studies even suggest their use may help prevent serious infections in systemic lupus erythematosus.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref>
</p><sec id="sec3.3.1"><title>Therapeutic potential in COVID-19</title><p id="p0080">Antimalarial drugs were at the forefront of the COVID-19 pandemic based on some early, uncontrolled, and small case series suggesting potential efficacy in the treatment of SARS-CoV-2 infection. Although in&#x000a0;vitro data suggest chloroquine and hydroxychloroquine both inhibit coronavirus,<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref>
<sup>,</sup>
<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> available clinical data do not suggest any benefit for the&#x000a0;treatment of patients critically ill with COVID-19.<xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref>, <xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref>
</p></sec><sec id="sec3.3.2"><title>Conclusions</title><p id="p0085">The current data show no significant risk of infection or infectious complications when antimalarials are used for the treatment of immune-mediated disease and therefore suggest low potential for harm in COVID-19 infection. However, data supporting the use of antimalarials for prevention or treatment of COVID-19 are lacking at present, and use of antimalarials outside of a hospital or clinical trial is cautioned against.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref>
</p></sec></sec><sec id="sec3.4"><title>Oral small molecules (azathioprine, mycophenolate mofetil, and cyclosporine)</title><p id="p0090">Using claims data, Schneeweiss et&#x000a0;al<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> examined the 6-month risk of serious and opportunistic infections in patients with atopic dermatitis. Compared with methotrexate, cyclosporine A had a 58% higher risk of overall infection (adjusted RR, 1.58; 95% CI, 1.17-2.15). In the same study, azathioprine had double the infection risk (RR, 1.78; 95% CI, 0.98-3.25), whereas mycophenolate mofetil tripled the risk (RR, 3.31; 95% CI, 1.94-5.64). A separate study comparing patients with systemic lupus erythematosus newly treated with mycophenolate mofetil or azathioprine found no differences in rates of serious infections.<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> Studies that examined the incidence of viral infections found that herpes zoster virus infections are increased with azathioprine<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref>
<sup>,</sup>
<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> and that cytomegalovirus infections are increased with mycophenolate mofetil,<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> although the latter appears to be limited to patients who have received a transplant.</p><sec id="sec3.4.1"><title>Therapeutic potential in COVID-19</title><p id="p0095">Some authors have suggested the use of cyclosporine in the treatment of COVID-19<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> based on its ability to inhibit coronavirus replication in&#x000a0;vitro.<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref>
<sup>,</sup>
<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> That said, its clinical efficacy has not been proven, and there&#x000a0;are no ongoing clinical trials in patients with COVID-19.</p></sec><sec id="sec3.4.2"><title>Conclusions</title><p id="p0100">Azathioprine, mycophenolate mofetil, and cyclosporine A increase the risk of infection relative to reference agents such as methotrexate, warranting increased caution and discussion with patients regarding starting or continuing therapy.</p></sec></sec><sec id="sec3.5"><title>Apremilast</title><p id="p0105">Long-term safety data from open-label extension studies in psoriasis and psoriatic arthritis do not show an increased risk of serious infections compared with placebo.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref>
<sup>,</sup>
<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> Similarly, URI and nasopharyngitis rates were comparable in the placebo-controlled phases of these studies.</p><sec id="sec3.5.1"><title>Conclusions</title><p id="p0110">The available data suggest a low risk of infection associated with the use of apremilast and, therefore, low potential for harm in COVID-19 infection.</p></sec></sec><sec id="sec3.6"><title>Janus kinase inhibitors</title><p id="p0115">The bulk of the safety data regarding Janus kinase (JAK) inhibitors comes from the use of tofacitinib in rheumatoid arthritis. Analysis of the most recent tofacitinib data from randomized controlled trials and long-term extension studies in rheumatoid arthritis reveals serious infection rates of 2.4 per 100 patient-years,<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> comparable to the event rates reported for biologic disease-modifying antirheumatic drugs<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref>
<sup>,</sup>
<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> and baricitinib.<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> A particular concern with JAK inhibition is the risk of varicella zoster virus reactivation and antiviral immunity. This appears to be a class effect due to impairment of the interferon antiviral response. It has been noted across all indications and occurs at an increased rate with both selective and nonselective JAK inhibitors.<xref rid="bib46" ref-type="bibr">46</xref>, <xref rid="bib47" ref-type="bibr">47</xref>, <xref rid="bib48" ref-type="bibr">48</xref>
</p><sec id="sec3.6.1"><title>Therapeutic potential in COVID-19</title><p id="p0120">Ruxolitinib (NCT04362137) and baricitinib (NCT04280705) are currently being evaluated in phase III clinical trials for potential therapeutic effect in patients critically ill with COVID-19. It is suggested that preferential inhibition of JAK1 and JAK2 significantly downregulates the production of interleukin (IL) 6 and interferon-&#x003b3;, both of which are implicated in the hyperinflammatory state seen in patients critically ill with COVID-19.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref>
<sup>,</sup>
<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref> Moreover, unlike tofacitinib, baricitinib and ruxolitinib have demonstrated antiviral activity via inhibition of receptor-mediated endocytosis of SARS-CoV-2 viral particles.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref>
</p></sec><sec id="sec3.6.2"><title>Additional concerns in COVID-19</title><p id="p0125">A high rate of venous thromboembolism (VTE) has been noted in COVID-19, occurring in up to one-third of critically ill patients, despite prophylactic anticoagulation.<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref>
<sup>,</sup>
<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> Because JAK inhibitors carry a &#x0201c;black box&#x000a0;warning&#x0201d; of increased VTE risk, there is reasonable concern that their use may increase the likelihood or severity of VTE when used in patients with COVID-19.<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref>
</p></sec><sec id="sec3.6.3"><title>Conclusions</title><p id="p0130">The use of JAK inhibitors is associated with an increased risk of serious infection, herpes zoster virus reactivation, and VTE. However, recent studies show potential direct antiviral and anti-inflammatory effects in COVID-19, seemingly unique to ruxolitinib and baricitinib. Taken together, there are insufficient data at this time to fully characterize the risk of harm or benefit in SARS-CoV-2 infection.</p></sec></sec><sec id="sec3.7"><title>Anticytokine biologic therapy</title><p id="p0135">Data from BIOBADADERM (Spanish Registry of&#x000a0;Adverse Events for Biological Therapy in Dermatological Diseases), a Spanish registry designed to study the safety of systemic therapy in psoriasis, showed an increased risk of overall infection with tumor necrosis factor (TNF) inhibitors compared with ustekinumab and nonbiologic drugs (acitretin, cyclosporine, and methotrexate). Of all TNF inhibitors, infliximab had the highest risk of infection (adjusted risk&#x000a0;ratio, 1.71; 95% CI, 1.1-2.65).<xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> Similarly, data from the large Psoriasis Longitudinal Assessment and Registry (PSOLAR) indicated a higher risk of serious infections with adalimumab and infliximab compared with nonbiologic drugs.<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> Conversely, no increased risk of serious infections was noted when ustekinumab and etanercept were compared with nonbiologic drugs.<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref>
</p><p id="p0140">Recently, Murrell et&#x000a0;al<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref> reviewed data from pivotal clinical trials in psoriasis and found that URIs were increased with TNF inhibitors compared with placebo but that URI rates were comparable between placebo and IL-17, IL-12/23, and IL-23 inhibitors. A different group also reviewed the clinical trial data for all 11 biologic therapies approved in psoriasis and found no significant increase in URI or influenza infection rates compared with placebo.<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref> In contrast, Wan et&#x000a0;al<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref> recently published a meta-estimate of pivotal clinical trials with 3 IL-17 inhibitors and found an increased risk of viral and nonviral URIs compared with placebo (odds ratio [OR], 1.56; 95% CI, 1.04-2.33).</p><sec id="sec3.7.1"><title>Conclusions</title><p id="p0145">Taken together, these data suggest a low risk of harm with IL-12/23 or IL-23 inhibition. Further data are needed regarding any potential increased risk of viral and nonviral URIs associated with IL-17 inhibition. The data presented indicate higher rates of overall infection and URIs with TNF inhibitors; however, ongoing trials investigating the therapeutic potential of adalimumab in the COVID-19&#x02013;related cytokine storm are still underway, and this precludes any definitive comments relating to the safety of TNF inhibitors in COVID-19.</p></sec></sec><sec id="sec3.8"><title>Rituximab</title><p id="p0150">Reactivation of chronic viral infections, such as hepatitis B and cytomegalovirus, is a rare yet well-reported adverse effect of rituximab.<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> Other viral illnesses, such as URIs and nasopharyngitis, are frequently reported, but clinical trial data in rheumatoid arthritis suggest similar overall rates of infections when rituximab is compared with methotrexate plus placebo.<xref rid="bib60" ref-type="bibr"><sup>60</sup></xref>
<sup>,</sup>
<xref rid="bib61" ref-type="bibr"><sup>61</sup></xref> Long-term observational studies also show that this risk remains stable with repeated infusions.<xref rid="bib62" ref-type="bibr"><sup>62</sup></xref>
<sup>,</sup>
<xref rid="bib63" ref-type="bibr"><sup>63</sup></xref> Data in the dermatologic literature are limited, but a randomized controlled trial in pemphigus vulgaris showed a similar rate of infections in the rituximab plus short-term steroid group compared with the steroid-only group.<xref rid="bib64" ref-type="bibr"><sup>64</sup></xref> However, it is worth noting that the rituximab group had lower cumulative exposure to prednisone.</p><p id="p0155">An important consideration is the risk of prolonged hypogammaglobulinemia, especially with repeated courses of rituximab.<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref> Cases characterized in the literature reveal an increased risk of URIs, pneumonias, and viral infections, including fatal instances of enteroviral meningoencephalitis.<xref rid="bib66" ref-type="bibr"><sup>66</sup></xref>
<sup>,</sup>
<xref rid="bib67" ref-type="bibr"><sup>67</sup></xref>
</p><sec id="sec3.8.1"><title>Particular concerns in COVID-19</title><p id="p0160">There is evidence to suggest that rituximab may blunt protective immune responses to vaccines. Indeed, impaired antibody responses are seen to both influenza and polysaccharide vaccines, with effects lasting up to 6&#x000a0;months after treatment with rituximab.<xref rid="bib68" ref-type="bibr"><sup>68</sup></xref>
<sup>,</sup>
<xref rid="bib69" ref-type="bibr"><sup>69</sup></xref>
</p></sec><sec id="sec3.8.2"><title>Conclusions</title><p id="p0165">The data suggest increased rates of infection and infectious complications associated with the use of rituximab. Together with a long immunologic half-life and prolonged impairment of vaccine immunity, there are significant potential safety concerns, suggesting a need for increased caution during the ongoing COVID-19 pandemic. To minimize harm, evaluation (and potential correction) of rituximab-induced hypogammaglobulinemia may be considered among patients who receive recurrent rituximab dosing.</p></sec></sec><sec id="sec3.9"><title>Dupilumab</title><p id="p0170">A comprehensive evaluation of infection risk with dupilumab was conducted by Eichenfield et&#x000a0;al.<xref rid="bib70" ref-type="bibr"><sup>70</sup></xref> Their analysis pooled data from 7 randomized controlled trials in atopic dermatitis, which showed similar infection rates per 100 patient-years in the treatment and placebo groups. Specifically, the rates of viral URIs and influenza infections were lower in the dupilumab groups compared with placebo. Similarly, an observational study by Schneeweiss et&#x000a0;al<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> found no increase in the rates of serious bacterial or opportunistic infections with dupilumab compared with methotrexate.</p><sec id="sec3.9.1"><title>Conclusions</title><p id="p0175">Data to date suggest a low risk of infection with the use of dupilumab and a low potential for harm in COVID-19.</p></sec></sec></sec><sec id="sec4"><title>Data from the COVID-19 pandemic</title><p id="p0180">One large case series and 2 registries have reported a combined total of 721 confirmed or highly suspected cases of COVID-19 in adult and pediatric immune-mediated inflammatory disease populations through May 19, 2020.<xref rid="bib71" ref-type="bibr">71</xref>, <xref rid="bib72" ref-type="bibr">72</xref>, <xref rid="bib73" ref-type="bibr">73</xref> The results are summarized in <xref rid="tbl2" ref-type="table">Table II</xref>
.<xref rid="bib71" ref-type="bibr">71</xref>, <xref rid="bib72" ref-type="bibr">72</xref>, <xref rid="bib73" ref-type="bibr">73</xref> Haberman et&#x000a0;al<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref> noted that those requiring hospitalization were more likely to have rheumatoid arthritis, had more comorbidities, were older, and had greater use of methotrexate, hydroxychloroquine, and corticosteroids. They also reported an overall incidence of hospitalization of 16%, which was comparable to the 26% incidence in patients with COVID-19 in the general population in New York.<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref> They concluded that baseline use of biologics was not associated with worse COVID-19 outcomes.<table-wrap position="float" id="tbl2"><label>Table II</label><caption><p>Summary of large case series and registry data of autoimmune disease patients infected or exposed to SARS-CoV-2</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Characteristics<xref rid="tbl2fnlowast" ref-type="table-fn">&#x02217;</xref></th><th colspan="3">Studies<hr/></th></tr><tr><th>Haberman et&#x000a0;al<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref></th><th>Gianfrancesco et&#x000a0;al<xref rid="bib72" ref-type="bibr"><sup>72</sup></xref></th><th>Brenner et&#x000a0;al<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref></th></tr></thead><tbody><tr><td>Total number of patients<xref rid="tbl2fndagger" ref-type="table-fn">&#x02020;</xref></td><td align="center">86</td><td align="center">110</td><td align="center">525</td></tr><tr><td>Confirmed cases of COVID-19</td><td align="center">59 (69)</td><td align="center">110 (100)</td><td align="center">525 (100)</td></tr><tr><td>Age, mean y</td><td align="center">46</td><td align="center">N/A<xref rid="tbl2fnddagger" ref-type="table-fn">&#x02021;</xref></td><td align="center">43</td></tr><tr><td>Female sex</td><td align="center">49 (57)</td><td align="center">79 (72)</td><td align="center">243 (46.3)</td></tr><tr><td>Most common diagnosis</td><td align="center">PsA: 21 (24)</td><td align="center">RA: 40 (36)</td><td align="center">CD: 312 (59.4)</td></tr><tr><td>Other diagnoses</td><td align="center">RA: 20 (23)</td><td align="center">PsA: 19 (17)</td><td align="center">UC: 203 (38.7)</td></tr><tr><td/><td align="center">CD: 20 (23)</td><td align="center">SLE: 19 (17)</td><td align="center">IBD unspecified: 7 (1.3)</td></tr><tr><td/><td align="center">UC: 17 (20)</td><td align="center">Other: 17 (15)<xref rid="tbl2fnsection" ref-type="table-fn">&#x000a7;</xref></td><td/></tr><tr><td/><td align="center">Psoriasis: 14 (16)</td><td align="center">AS: 7 (6)</td><td/></tr><tr><td/><td align="center">AS: 9 (10)</td><td align="center">Vasculitis: 7 (6)</td><td/></tr><tr><td/><td/><td align="center">SjS: 5 (5)</td><td/></tr><tr><td>Medications</td><td/><td/><td/></tr><tr><td>Biologic drugs</td><td align="center">TNFi: 38 (44)</td><td align="center">Unspecified: 49 (45)</td><td align="center">TNFi alone: 176 (33.5)</td></tr><tr><td/><td align="center">IL-17i: 6 (7)</td><td/><td align="center">IL-12/23i: 55 (10.5)</td></tr><tr><td/><td align="center">IL-12/23i: 6 (7)</td><td/><td align="center">TNFi&#x000a0;+&#x000a0;DMARD: 52 (9.9)</td></tr><tr><td/><td align="center">IL-23i: 3 (3)</td><td/><td align="center">&#x003b1;-Integrin: 50 (9.5)</td></tr><tr><td>JAKi</td><td align="center">6 (7)</td><td align="center">5 (5)</td><td align="center">8 (1.5)</td></tr><tr><td>csDMARD</td><td align="center">MTX: 17 (20)</td><td align="center">69 (63)</td><td align="center">110 (21)</td></tr><tr><td>Hydroxychloroquine</td><td align="center">8 (9)</td><td align="center">N/A</td><td align="center">0</td></tr><tr><td>Hospitalization</td><td align="center">14 (16)</td><td align="center">39 (35)</td><td align="center">161 (31)</td></tr><tr><td>Deaths</td><td align="center">1 (1)</td><td align="center">6 (5)</td><td align="center">16 (3)</td></tr></tbody></table><table-wrap-foot><fn><p><italic>AS</italic>, Ankylosing spondylitis; <italic>CD</italic>, Crohn's disease; <italic>COVID-19</italic>, coronavirus disease 2019; <italic>csDMARD</italic>, conventional synthetic disease-modifying antirheumatic drug; <italic>IBD</italic>, inflammatory bowel disease; <italic>IL</italic>, interleukin; <italic>JAK</italic>, Janus kinase inhibitor; <italic>MTX</italic>, methotrexate; <italic>N/A</italic>, not available; <italic>PsA</italic>, psoriatic arthritis; <italic>RA</italic>, rheumatoid arthritis; <italic>SARS-Cov-2</italic>, severe acute respiratory syndrome coronavirus 2; <italic>SjS</italic>, Sj&#x000f6;gren syndrome; <italic>SLE</italic>, systemic lupus erythematosus; <italic>TNFi</italic>, tumor necrosis factor-&#x003b1; inhibitor; <italic>UC</italic>, ulcerative colitis.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnlowast"><label>&#x02217;</label><p id="ntpara0030">Data are shown as number (%) or as indicated otherwise.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fndagger"><label>&#x02020;</label><p id="ntpara0035">Includes both confirmed and highly suspected cases of COVID-19.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnddagger"><label>&#x02021;</label><p id="ntpara0040">20% of patients were aged &#x0003e;65&#x000a0;years.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnsection"><label>&#x000a7;</label><p id="ntpara0045">Other included (all with n&#x000a0;&#x0003c;&#x000a0;5): inflammatory myopathy, ocular inflammation, other inflammatory arthritis, polymyalgia rheumatica, sarcoidosis, systemic sclerosis, osteoporosis, psoriasis, isolated pulmonary capillaritis, gout, and autoinflammatory disease.</p></fn></table-wrap-foot></table-wrap></p><p id="p0185">In the inflammatory bowel disease registry, 16 deaths (3%) were identified, with half occurring in patients aged &#x0003e;70&#x000a0;years, whereas no deaths were noted in patients aged &#x0003c;30&#x000a0;years. On multivariate analysis, Brenner et&#x000a0;al<xref rid="bib73" ref-type="bibr"><sup>73</sup></xref> reported a strong association between systemic steroids and the composite outcome of intensive care unit admission, ventilator use, and death (adjusted OR, 6.9; 95% CI, 2.3-20.5). In contrast, no association was seen between TNF inhibitor monotherapy and poor COVID-19 outcomes (adjusted OR, 0.90; 95% CI, 0.37-2.17). Although the authors did not report on the use of IL-12/23 inhibitors, as of May 19, 2020, data from the registry (available for viewing on <ext-link ext-link-type="uri" xlink:href="http://covidibd.org" id="intref0010">covidibd.org</ext-link>) revealed 1170 cases, with 9% (100 of 1170) of patients having poor outcomes. Among subgroups, 23% (23 of 98) of steroid users had poor outcomes compared with only 2% (8 of 337) of patients on TNF inhibitor monotherapy and 3% (3 of 112) of patients on IL-12/23 inhibitors.</p><p id="p0190">With regards to infection risk, a case-control study by Damiani et&#x000a0;al<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref> evaluated 1193 patients with psoriasis and identified only 16 cases of COVID-19 from February 21 to April 9, 2020. Compared with the general population of Lombardy, patients on biologics had a higher risk of testing positive for COVID-19 (OR, 3.43; 95% CI, 2.25-5.73) and hospitalization (OR, 3.59; 95% CI, 1.49-8.63).</p><sec id="sec4.1"><sec id="sec4.1.1"><title>Conclusion</title><p id="p0195">Most of the patients on systemic immunosuppressive or immunomodulatory therapy included in these studies did not require hospitalization, and death remained a rare outcome. However, systemic corticosteroid use in this patient population appeared to increase the risk of poor outcomes in COVID-19.</p></sec></sec></sec><sec id="sec5"><title>Discussion and recommendations</title><p id="p0200">We believe a patient-centered approach, with shared decision making informed by the data presented here, will help mitigate risk to our patients. Factors to consider are summarized in <xref rid="tbl1" ref-type="table">Table I</xref>. Our interpretation of the literature based on the highest quality of evidence available to date is found in <xref rid="tbl3" ref-type="table">Table III</xref>
. The overarching principles are that immunosuppressive and immunomodulatory therapy can be safely initiated or continued in most patients. Physicians should alter and optimize regimens in favor of lower-risk options where possible, and as outlined more specifically in <xref rid="tbl3" ref-type="table">Table III</xref> and <xref rid="fig1" ref-type="fig">Fig 1</xref>
.<table-wrap position="float" id="tbl3"><label>Table III</label><caption><p>Guidance statements for management of immunosuppression during the coronavirus disease 2019 (<italic>COVID-19</italic>) pandemic<xref rid="tbl3fnlowast" ref-type="table-fn">&#x02217;</xref></p></caption><table frame="hsides" rules="groups"><tbody><tr><td>Patients well-controlled on maintenance therapy</td><td>We suggest continuing immunosuppressive/immunomodulatory therapy at the lowest necessary effective dose, because immunosuppression alone does not appear to predict poor COVID-19 outcomes.<break/>We do note the following exceptions:<list list-type="simple" id="olist0015"><list-item id="o0040"><label>a.</label><p id="p0240">Long-term systemic steroids should be tapered to daily doses &#x0003c;10&#x000a0;mg prednisone equivalent, if safe to do so.</p></list-item><list-item id="o0045"><label>b.</label><p id="p0245">Patients on recurrent rituximab dosing may benefit from immunoglobulin level testing. If hypogammaglobulinemia exists, consider altering/delaying dose or initiating immunoglobulin therapy, or both.</p></list-item></list></td></tr><tr><td>Patients requiring initiation of treatment</td><td>We suggest the following:<list list-type="simple" id="olist0020"><list-item id="o0050"><label>a.</label><p id="p0250">On the basis of disease severity and baseline risk, consider favoring low-risk immunomodulatory agents (eg, apremilast, hydroxychloroquine, methotrexate) over immunosuppressive agents with a higher known or suspected risk of infection (see <xref rid="tbl2" ref-type="table">Table II</xref>).</p></list-item><list-item id="o0055"><label>b.</label><p id="p0255">When medically appropriate, opt for short courses of low to moderate doses of systemic corticosteroids over high-dose regimens (eg, &#x0003c;20&#x000a0;mg prednisone equivalent daily for &#x0003c;2&#x000a0;weeks); if needed for maintenance therapy, consider doses &#x0003c;10&#x000a0;mg daily.</p></list-item><list-item id="o0060"><label>c.</label><p id="p0260">When possible, avoid starting rituximab, due to its prolonged B-cell&#x02013;depleting effects, if equally efficacious alternative therapies are available; exceptions include mucous membrane blistering disorders.</p></list-item><list-item id="o0065"><label>d.</label><p id="p0265">If possible, use alternatives to cyclosporine and other agents requiring intensive toxicity/safety monitoring.</p></list-item></list></td></tr><tr><td>Patients with active COVID-19 infection, including COVID-19<sup>+</sup> testing (even in the absence of symptoms)</td><td>Although the potential benefit of immunosuppression is being studied in the context of cytokine storm, we suggest that, if possible, immunosuppressive therapy be held in patients testing positive for COVID-19, even if asymptomatic, with the concern being the complication of bacterial infections and pneumonia. Many systemic immunosuppressive drugs have long half-lives, and temporary cessation of therapy is unlikely to result in disease flare. Individual discussions may be considered for severe flares with potentially organ-threatening manifestations. Treatment can resume after recovery (refer to Centers for Disease Control and Prevention or local health authority for recovery criteria).<break/>Exceptions to the above include:<list list-type="simple" id="olist0025"><list-item id="o0070"><label>a.</label><p id="p0270">Systemic steroids may be tapered but not stopped abruptly. Providers should follow recommendations for corticosteroid stress doses in critically ill patients.</p></list-item><list-item id="o0075"><label>b.</label><p id="p0275">Drugs with minimal immunosuppressive potential (e.g., apremilast, antimalarials) may be continued after thorough patient assessment (refer to <xref rid="tbl1" ref-type="table">Table I</xref>).</p></list-item></list></td></tr><tr><td>Patients with active immune-mediated skin disease</td><td><list list-type="simple" id="olist0030"><list-item id="o0080"><label>a.</label><p id="p0280">When possible, maximize/optimize nonimmunosuppressive therapy, such as topical steroids, immunomodulatory agents (eg, apremilast, antimalarials, and retinoids), and anti-inflammatory medications (eg, tetracycline or macrolide class antibiotics).</p></list-item><list-item id="o0085"><label>b.</label><p id="p0285">High-dose systemic corticosteroids should be avoided where possible, and taper plans should be kept to the minimum necessary dose and duration.</p></list-item></list></td></tr></tbody></table><table-wrap-foot><fn id="tbl3fnlowast"><label>&#x02217;</label><p id="ntpara0050">With limited COVID-specific safety data available on any given treatment, it is challenging to produce firm recommendations on the safety of immunosuppression in the context of the current pandemic. Notably, our guidance statements are based on expert opinion and interpretation of safety data deemed most relevant rather than on formal guidelines derived from high-quality comparative studies. Limitations include the heterogeneity of the safety data encompassing various autoimmune conditions and the limited reports available on the status of immunosuppressed patients affected by COVID-19. The applicability of the information and recommendations provided here are limited by the rapidly evolving nature of the COVID-19 pandemic, in addition to patient-specific and local health care constraints. Decisions should ultimately be individualized to a specific scenario, and reflective of shared-decision making between provider and patient.</p></fn></table-wrap-foot></table-wrap><fig id="fig1"><label>Fig&#x000a0;1</label><caption><p>Drug safety recommendations in the context of the coronavirus disease 2019 (COVID-19) pandemic. <italic>CMV</italic>, Cytomegalovirus; <italic>DVT</italic>, deep venous thrombosis; <italic>HZV</italic>, herpes zoster virus; <italic>IL</italic>, interleukin; <italic>PE</italic>, pulmonary embolus; <italic>URI</italic>, upper respiratory infection.</p></caption><graphic xlink:href="gr1_lrg"/></fig></p><p id="p0205">Further data regarding the safety of these agents are needed and constitute a key unmet need for our patients.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Wakkee</surname><given-names>M.</given-names></name><name><surname>de Vries</surname><given-names>E.</given-names></name><name><surname>van den Haak</surname><given-names>P.</given-names></name><name><surname>Nijsten</surname><given-names>T.</given-names></name></person-group><article-title>Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort</article-title><source>J Am Acad Dermatol</source><volume>65</volume><issue>6</issue><year>2011</year><fpage>1135</fpage><lpage>1144</lpage><pub-id pub-id-type="pmid">21664719</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Herrinton</surname><given-names>L.J.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Goldfien</surname><given-names>R.</given-names></name><name><surname>Michaels</surname><given-names>M.A.</given-names></name><name><surname>Tran</surname><given-names>T.N.</given-names></name></person-group><article-title>Risk of serious infection for patients with systemic lupus erythematosus starting glucocorticoids with or without antimalarials</article-title><source>J Rheumatol</source><volume>43</volume><issue>8</issue><year>2016</year><fpage>1503</fpage><lpage>1509</lpage><pub-id pub-id-type="pmid">27370880</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Perez-Chada</surname><given-names>L.M.</given-names></name><name><surname>Merola</surname><given-names>J.F.</given-names></name></person-group><article-title>Comorbidities associated with psoriatic arthritis: review and update</article-title><source>Clin Immunol</source><volume>214</volume><year>2020</year><fpage>108397</fpage><pub-id pub-id-type="pmid">32229290</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name></person-group><article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China</article-title><source>JAMA</source><volume>323</volume><issue>11</issue><year>2020</year><fpage>1061</fpage><lpage>1069</lpage></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>D.S.</given-names></name><name><surname>Azhar</surname><given-names>E.I.</given-names></name><name><surname>Kim</surname><given-names>Y.-J.</given-names></name><name><surname>Memish</surname><given-names>Z.A.</given-names></name><name><surname>Oh</surname><given-names>M.</given-names></name><name><surname>Zumla</surname><given-names>A.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission</article-title><source>Lancet Infect Dis</source><volume>18</volume><issue>8</issue><year>2018</year><fpage>e217</fpage><lpage>e227</lpage><pub-id pub-id-type="pmid">29680581</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>D&#x02019;Antiga</surname><given-names>L.</given-names></name></person-group><article-title>Coronaviruses and immunosuppressed patients: the facts during the third epidemic</article-title><source>Liver Transpl</source><volume>26</volume><issue>6</issue><year>2020</year><fpage>832</fpage><lpage>834</lpage><pub-id pub-id-type="pmid">32196933</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>M.-F.</given-names></name><name><surname>Ooi</surname><given-names>G.C.</given-names></name><name><surname>Lam</surname><given-names>B.</given-names></name></person-group><article-title>An indolent case of severe acute respiratory syndrome</article-title><source>Am J Respir Crit Care Med</source><volume>169</volume><issue>1</issue><year>2004</year><fpage>125</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">14695107</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.-H.</given-names></name><name><surname>Ko</surname><given-names>J.-H.</given-names></name><name><surname>Park</surname><given-names>G.E.</given-names></name></person-group><article-title>Atypical presentations of MERS-CoV infection in immunocompromised hosts</article-title><source>J Infect Chemother</source><volume>23</volume><issue>11</issue><year>2017</year><fpage>769</fpage><lpage>773</lpage><pub-id pub-id-type="pmid">28545936</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Prescott</surname><given-names>J.</given-names></name><name><surname>Falzarano</surname><given-names>D.</given-names></name><name><surname>de Wit</surname><given-names>E.</given-names></name></person-group><article-title>Pathogenicity and viral shedding of MERS-CoV in immunocompromised rhesus macaques</article-title><source>Front Immunol</source><volume>9</volume><year>2018</year><fpage>205</fpage><pub-id pub-id-type="pmid">29483914</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Merad</surname><given-names>M.</given-names></name><name><surname>Martin</surname><given-names>J.C.</given-names></name></person-group><article-title>Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages</article-title><source>Nat Rev Immunol</source><volume>20</volume><issue>6</issue><year>2020</year><fpage>355</fpage><lpage>362</lpage><pub-id pub-id-type="pmid">32376901</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Stuck</surname><given-names>A.E.</given-names></name><name><surname>Minder</surname><given-names>C.E.</given-names></name><name><surname>Frey</surname><given-names>F.J.</given-names></name></person-group><article-title>Risk of infectious complications in patients taking glucocorticosteroids</article-title><source>Rev Infect Dis</source><volume>11</volume><issue>6</issue><year>1989</year><fpage>954</fpage><lpage>963</lpage><pub-id pub-id-type="pmid">2690289</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Migita</surname><given-names>K.</given-names></name><name><surname>Sasaki</surname><given-names>Y.</given-names></name><name><surname>Ishizuka</surname><given-names>N.</given-names></name></person-group><article-title>Glucocorticoid therapy and the risk of infection in patients with newly diagnosed autoimmune disease</article-title><source>Medicine (Baltimore)</source><volume>92</volume><issue>5</issue><year>2013</year><fpage>285</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">23982055</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>J.D.</given-names></name><name><surname>Reed</surname><given-names>G.</given-names></name><name><surname>Kremer</surname><given-names>J.M.</given-names></name></person-group><article-title>Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry</article-title><source>Ann Rheum Dis</source><volume>69</volume><issue>2</issue><year>2010</year><fpage>380</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">19359261</pub-id></element-citation></ref><ref id="bib14"><label>14</label><mixed-citation publication-type="other" id="oref14">Horby P, Lim WS, Emberson J, et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. medRxiv. Published online January 1, 2020:2020.06.22.20137273. <pub-id pub-id-type="doi">10.1101/2020.06.22.20137273</pub-id>.</mixed-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N.</given-names></name><name><surname>Allen Chan</surname><given-names>K.C.</given-names></name><name><surname>Hui</surname><given-names>D.S.</given-names></name></person-group><article-title>Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients</article-title><source>J Clin Virol</source><volume>31</volume><issue>4</issue><year>2004</year><fpage>304</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">15494274</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>D.S.</given-names></name></person-group><article-title>Systemic corticosteroid therapy may delay viral clearance in patients with Middle East respiratory syndrome coronavirus infection</article-title><source>Am J Respir Crit Care Med</source><volume>197</volume><issue>6</issue><year>2017</year><fpage>700</fpage><lpage>701</lpage></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>Y.M.</given-names></name><name><surname>Mandourah</surname><given-names>Y.</given-names></name><name><surname>Al-Hameed</surname><given-names>F.</given-names></name></person-group><article-title>Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome</article-title><source>Am J Respir Crit Care Med</source><volume>197</volume><issue>6</issue><year>2017</year><fpage>757</fpage><lpage>767</lpage></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Lansbury</surname><given-names>L.</given-names></name><name><surname>Rodrigo</surname><given-names>C.</given-names></name><name><surname>Leonardi-Bee</surname><given-names>J.</given-names></name><name><surname>Nguyen-Van-Tam</surname><given-names>J.</given-names></name><name><surname>Lim</surname><given-names>W.S.</given-names></name></person-group><article-title>Corticosteroids as adjunctive therapy in the treatment of influenza</article-title><source>Cochrane Database Syst Rev</source><volume>2</volume><issue>2</issue><year>2019</year><fpage>CD010406</fpage><pub-id pub-id-type="pmid">30798570</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>Y.-N.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Liang</surname><given-names>B.-M.</given-names></name><name><surname>Liang</surname><given-names>Z.-A.</given-names></name></person-group><article-title>The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis</article-title><source>Crit Care</source><volume>23</volume><issue>1</issue><year>2019</year><fpage>99</fpage><pub-id pub-id-type="pmid">30917856</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>A.</given-names></name><name><surname>Ahmed</surname><given-names>M.</given-names></name><name><surname>Conway</surname><given-names>R.</given-names></name><name><surname>Carey</surname><given-names>J.J.</given-names></name></person-group><article-title>Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis</article-title><source>J Clin Med</source><volume>8</volume><issue>1</issue><year>2018</year><fpage>15</fpage></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>D.H.</given-names></name><name><surname>Glynn</surname><given-names>R.J.</given-names></name><name><surname>Karlson</surname><given-names>E.W.</given-names></name></person-group><article-title>Adverse effects of low-dose methotrexate: a randomized trial</article-title><source>Ann Intern Med</source><volume>172</volume><issue>6</issue><year>2020</year><fpage>369</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">32066146</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Ruiz-Irastorza</surname><given-names>G.</given-names></name><name><surname>Ramos-Casals</surname><given-names>M.</given-names></name><name><surname>Brito-Zeron</surname><given-names>P.</given-names></name><name><surname>Khamashta</surname><given-names>M.A.</given-names></name></person-group><article-title>Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review</article-title><source>Ann Rheum Dis</source><volume>69</volume><issue>01</issue><year>2010</year><fpage>20</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">19103632</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Bernatsky</surname><given-names>S.</given-names></name><name><surname>Hudson</surname><given-names>M.</given-names></name><name><surname>Suissa</surname><given-names>S.</given-names></name></person-group><article-title>Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis</article-title><source>Rheumatology (Oxford)</source><volume>46</volume><issue>7</issue><year>2007</year><fpage>1157</fpage><lpage>1160</lpage><pub-id pub-id-type="pmid">17478469</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>X.</given-names></name><name><surname>Ye</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name></person-group><article-title>In&#x000a0;vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [e-pub ahead of print]</article-title><source>Clin Infect Dis</source><year>2020</year><pub-id pub-id-type="doi">10.1093/cid/ciaa237</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Keyaerts</surname><given-names>E.</given-names></name><name><surname>Vijgen</surname><given-names>L.</given-names></name><name><surname>Maes</surname><given-names>P.</given-names></name><name><surname>Neyts</surname><given-names>J.</given-names></name><name><surname>Ranst</surname><given-names>M.V.</given-names></name></person-group><article-title>In&#x000a0;vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine</article-title><source>Biochem Biophys Res Commun</source><volume>323</volume><issue>1</issue><year>2004</year><fpage>264</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">15351731</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Pastick</surname><given-names>K.A.</given-names></name><name><surname>Okafor</surname><given-names>E.C.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name></person-group><article-title>Review: hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19)</article-title><source>Open Forum Infect Dis</source><volume>7</volume><issue>4</issue><year>2020</year><fpage>ofaa130</fpage><pub-id pub-id-type="pmid">32363212</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Mahevas</surname><given-names>M.</given-names></name><name><surname>Tran</surname><given-names>V.-T.</given-names></name><name><surname>Roumier</surname><given-names>M.</given-names></name></person-group><article-title>No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial [preprint]</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.04.10.20060699</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Geleris</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Platt</surname><given-names>J.</given-names></name></person-group><article-title>Observational study of hydroxychloroquine in hospitalized patients with Covid-19</article-title><source>N Engl J Med</source><volume>382</volume><issue>25</issue><year>2020</year><fpage>2411</fpage><lpage>2418</lpage><pub-id pub-id-type="pmid">32379955</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Magagnoli</surname><given-names>J.</given-names></name><name><surname>Narendran</surname><given-names>S.</given-names></name><name><surname>Pereira</surname><given-names>F.</given-names></name></person-group><article-title>Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 [preprint]</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.04.16.20065920</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>W.</given-names></name><name><surname>Cao</surname><given-names>Z.</given-names></name><name><surname>Han</surname><given-names>M.</given-names></name></person-group><article-title>Hydroxychloroquine in patients mainly with mild to moderate coronavirus disease 2019: an open-label, randomized, controlled trial</article-title><source>BMJ</source><volume>369</volume><year>2020</year><fpage>m1849</fpage><pub-id pub-id-type="pmid">32409561</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="other" id="sref31"><person-group person-group-type="author"><name><surname>US Food and Drug Administration</surname></name></person-group><article-title>FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems: does not affect FDA-approved uses for malaria, lupus, and rheumatoid arthritis</article-title><comment>Available at:</comment><ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or" id="intref0015">https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or</ext-link><year>2020</year></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Schneeweiss</surname><given-names>M.C.</given-names></name><name><surname>Perez-Chada</surname><given-names>L.</given-names></name><name><surname>Merola</surname><given-names>J.F.</given-names></name></person-group><article-title>Comparative safety of systemic immuno-modulatory medications in adults with atopic dermatitis [e-pub ahead of print]</article-title><source>J Am Acad Dermatol</source><year>2019</year><pub-id pub-id-type="doi">10.1016/j.jaad.2019.05.073</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Feldman</surname><given-names>C.H.</given-names></name><name><surname>Marty</surname><given-names>F.M.</given-names></name><name><surname>Winkelmayer</surname><given-names>W.C.</given-names></name></person-group><article-title>Comparative rates of serious infections among patients with systemic lupus erythematosus receiving immunosuppressive medications</article-title><source>Arthritis Rheumatol</source><volume>69</volume><issue>2</issue><year>2017</year><fpage>387</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">27589220</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Wisniewski</surname><given-names>A.</given-names></name><name><surname>Kirchgesner</surname><given-names>J.</given-names></name><name><surname>Seksik</surname><given-names>P.</given-names></name></person-group><article-title>Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines</article-title><source>United European Gastroenterol J</source><volume>8</volume><issue>3</issue><year>2020</year><fpage>303</fpage><lpage>313</lpage></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Wolfe</surname><given-names>F.</given-names></name><name><surname>Michaud</surname><given-names>K.</given-names></name><name><surname>Chakravarty</surname><given-names>E.F.</given-names></name></person-group><article-title>Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders</article-title><source>Rheumatology (Oxford)</source><volume>45</volume><issue>11</issue><year>2006</year><fpage>1370</fpage><lpage>1375</lpage><pub-id pub-id-type="pmid">17003175</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><collab>The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group</collab></person-group><article-title>A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation</article-title><source>Transplantation</source><volume>61</volume><issue>7</issue><year>1996</year><fpage>1029</fpage><lpage>1037</lpage><pub-id pub-id-type="pmid">8623181</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Cour</surname><given-names>M.</given-names></name><name><surname>Ovize</surname><given-names>M.</given-names></name><name><surname>Argaud</surname><given-names>L.</given-names></name></person-group><article-title>Cyclosporine A: a valid candidate to treat COVID-19 patients with acute respiratory failure?</article-title><source>Crit Care</source><volume>24</volume><issue>1</issue><year>2020</year><fpage>276</fpage><pub-id pub-id-type="pmid">32487139</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>de Wilde</surname><given-names>A.H.</given-names></name><name><surname>Zevenhoven-Dobbe</surname><given-names>J.C.</given-names></name><name><surname>van der Meer</surname><given-names>Y.</given-names></name></person-group><article-title>Cyclosporin A inhibits the replication of diverse coronaviruses</article-title><source>J Gen Virol</source><volume>92</volume><issue>Pt 11</issue><year>2011</year><fpage>2542</fpage><lpage>2548</lpage><pub-id pub-id-type="pmid">21752960</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y.</given-names></name><name><surname>Sato</surname><given-names>Y.</given-names></name><name><surname>Sasaki</surname><given-names>T.</given-names></name></person-group><article-title>Suppression of coronavirus replication by cyclophilin inhibitors</article-title><source>Viruses</source><volume>5</volume><issue>5</issue><year>2013</year><fpage>1250</fpage><lpage>1260</lpage><pub-id pub-id-type="pmid">23698397</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Crowley</surname><given-names>J.</given-names></name><name><surname>Tha&#x000e7;i</surname><given-names>D.</given-names></name><name><surname>Joly</surname><given-names>P.</given-names></name></person-group><article-title>Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for &#x02265;156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)</article-title><source>J Am Acad Dermatol</source><volume>77</volume><issue>2</issue><year>2017</year><fpage>310</fpage><lpage>317.e1</lpage><pub-id pub-id-type="pmid">28416342</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Kavanaugh</surname><given-names>A.</given-names></name><name><surname>Gladman</surname><given-names>D.D.</given-names></name><name><surname>Edwards</surname><given-names>C.J.</given-names></name></person-group><article-title>Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1&#x02013;3 pooled analysis</article-title><source>Arthritis Res Ther</source><volume>21</volume><issue>1</issue><year>2019</year><fpage>118</fpage><pub-id pub-id-type="pmid">31077258</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Wollenhaupt</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>E.-B.</given-names></name><name><surname>Curtis</surname><given-names>J.R.</given-names></name></person-group><article-title>Safety and efficacy of tofacitinib for up to 9.5&#x02009;years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study</article-title><source>Arthritis Res Ther</source><volume>21</volume><issue>1</issue><year>2019</year><fpage>89</fpage><pub-id pub-id-type="pmid">30953540</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Vieira</surname><given-names>M.-C.</given-names></name><name><surname>Zwillich</surname><given-names>S.H.</given-names></name><name><surname>Jansen</surname><given-names>J.P.</given-names></name><name><surname>Smiechowski</surname><given-names>B.</given-names></name><name><surname>Spurden</surname><given-names>D.</given-names></name><name><surname>Wallenstein</surname><given-names>G.V.</given-names></name></person-group><article-title>Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: results from a network meta-analysis</article-title><source>Clin Ther</source><volume>38</volume><issue>12</issue><year>2016</year><fpage>2628</fpage><lpage>2641.e5</lpage><pub-id pub-id-type="pmid">27889300</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Strand</surname><given-names>V.</given-names></name><name><surname>Ahadieh</surname><given-names>S.</given-names></name><name><surname>DeMasi</surname><given-names>R.</given-names></name></person-group><article-title>THU0211 Meta-analysis of serious infections with baricitinib, tofacitinib and biologic DMARDs in rheumatoid arthritis [abstract]</article-title><source>Ann Rheum Dis</source><volume>76</volume><issue>Suppl 2</issue><year>2017</year><fpage>284</fpage></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Smolen</surname><given-names>J.S.</given-names></name><name><surname>Genovese</surname><given-names>M.C.</given-names></name><name><surname>Takeuchi</surname><given-names>T.</given-names></name></person-group><article-title>Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment</article-title><source>J Rheumatol</source><volume>46</volume><issue>1</issue><year>2019</year><fpage>7</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">30219772</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Winthrop</surname><given-names>K.L.</given-names></name><name><surname>Curtis</surname><given-names>J.R.</given-names></name><name><surname>Lindsey</surname><given-names>S.</given-names></name></person-group><article-title>Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy</article-title><source>Arthritis Rheumatol</source><volume>69</volume><issue>10</issue><year>2017</year><fpage>1960</fpage><lpage>1968</lpage><pub-id pub-id-type="pmid">28845604</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Olivera</surname><given-names>P.A.</given-names></name><name><surname>Lasa</surname><given-names>J.S.</given-names></name><name><surname>Bonovas</surname><given-names>S.</given-names></name><name><surname>Danese</surname><given-names>S.</given-names></name><name><surname>Peyrin-Biroulet</surname><given-names>L.</given-names></name></person-group><article-title>Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis</article-title><source>Gastroenterology</source><volume>158</volume><issue>6</issue><year>2020</year><fpage>1554</fpage><lpage>1573.e12</lpage><pub-id pub-id-type="pmid">31926171</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Winthrop</surname><given-names>K.L.</given-names></name><name><surname>Lebwohl</surname><given-names>M.</given-names></name><name><surname>Cohen</surname><given-names>A.D.</given-names></name></person-group><article-title>Herpes zoster in psoriasis patients treated with tofacitinib</article-title><source>J Am Acad Dermatol</source><volume>77</volume><issue>2</issue><year>2017</year><fpage>302</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">28711084</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>McGonagle</surname><given-names>D.</given-names></name><name><surname>Sharif</surname><given-names>K.</given-names></name><name><surname>O'Regan</surname><given-names>A.</given-names></name><name><surname>Bridgewood</surname><given-names>C.</given-names></name></person-group><article-title>The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease</article-title><source>Autoimmun Rev</source><volume>19</volume><issue>6</issue><year>2020</year><fpage>102537</fpage><pub-id pub-id-type="pmid">32251717</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Stebbing</surname><given-names>J.</given-names></name><name><surname>Phelan</surname><given-names>A.</given-names></name><name><surname>Griffin</surname><given-names>I.</given-names></name></person-group><article-title>COVID-19: combining antiviral and anti-inflammatory treatments</article-title><source>Lancet Infect Dis</source><volume>20</volume><issue>4</issue><year>2020</year><fpage>400</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">32113509</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Wichmann</surname><given-names>D.</given-names></name><name><surname>Sperhake</surname><given-names>J.-P.</given-names></name><name><surname>L&#x000fc;tgehetmann</surname><given-names>M.</given-names></name></person-group><article-title>Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study [e-pub ahead of print]</article-title><source>Ann Intern Med</source><year>2020</year><pub-id pub-id-type="doi">10.7326/M20-2003</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Klok</surname><given-names>F.A.</given-names></name><name><surname>Kruip</surname><given-names>M.J.H.A.</given-names></name><name><surname>van der Meer</surname><given-names>N.J.M.</given-names></name></person-group><article-title>Incidence of thrombotic complications in critically ill ICU patients with COVID-19</article-title><source>Thromb Res</source><volume>191</volume><year>2020</year><fpage>145</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">32291094</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Nash</surname><given-names>P.</given-names></name></person-group><article-title>2019 update: EULAR RA management recommendations, efficacy and safety systematic literature reviews</article-title><source>Ann Rheum Dis</source><volume>79</volume><issue>6</issue><year>2020</year><fpage>679</fpage><lpage>680</lpage><pub-id pub-id-type="pmid">32033940</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>D&#x000e1;vila-Seijo</surname><given-names>P.</given-names></name><name><surname>Dauden</surname><given-names>E.</given-names></name><name><surname>Descalzo</surname><given-names>M.A.</given-names></name></person-group><article-title>Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM Registry</article-title><source>J Investig Dermatol</source><volume>137</volume><issue>2</issue><year>2017</year><fpage>313</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">27677836</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Kalb</surname><given-names>R.E.</given-names></name><name><surname>Fiorentino</surname><given-names>D.F.</given-names></name><name><surname>Lebwohl</surname><given-names>M.G.</given-names></name></person-group><article-title>Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)</article-title><source>JAMA Dermatol</source><volume>151</volume><issue>9</issue><year>2015</year><fpage>961</fpage><lpage>969</lpage><pub-id pub-id-type="pmid">25970800</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Lebwohl</surname><given-names>M.</given-names></name><name><surname>Rivera-Oyola</surname><given-names>R.</given-names></name><name><surname>Murrell</surname><given-names>D.F.</given-names></name></person-group><article-title>Should biologics for psoriasis be interrupted in the era of COVID-19?</article-title><source>J Am Acad Dermatol</source><volume>82</volume><issue>5</issue><year>2020</year><fpage>1217</fpage><lpage>1218</lpage><pub-id pub-id-type="pmid">32199889</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Brownstone</surname><given-names>N.D.</given-names></name><name><surname>Thibodeaux</surname><given-names>Q.G.</given-names></name><name><surname>Reddy</surname><given-names>V.D.</given-names></name></person-group><article-title>Novel coronavirus disease (COVID-19) and biologic therapy in psoriasis: infection risk and patient counseling in uncertain times</article-title><source>Dermatol Ther (Heidelb)</source><volume>10</volume><year>2020</year><fpage>339</fpage><lpage>349</lpage></element-citation></ref><ref id="bib58"><label>58</label><mixed-citation publication-type="other" id="sref58">Wan MT, Shin DB, Winthrop KL, Gelfand JM. The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17&#x02013;pathway inhibiting biologics: a meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic [e-pub ahead of print]. <italic>J Am Acad Dermatol.</italic> 2020. <pub-id pub-id-type="doi">10.1016/j.jaad.2020.05.035</pub-id>. Accessed May 19, 2020.</mixed-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Aksoy</surname><given-names>S.</given-names></name><name><surname>Harputluoglu</surname><given-names>H.</given-names></name><name><surname>Kilickap</surname><given-names>S.</given-names></name></person-group><article-title>Rituximab-related viral infections in lymphoma patients</article-title><source>Leuk Lymphoma</source><volume>48</volume><issue>7</issue><year>2007</year><fpage>1307</fpage><lpage>1312</lpage><pub-id pub-id-type="pmid">17613758</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Emery</surname><given-names>P.</given-names></name><name><surname>Deodhar</surname><given-names>A.</given-names></name><name><surname>Rigby</surname><given-names>W.F.</given-names></name></person-group><article-title>Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological na&#x000ef;ve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))</article-title><source>Ann Rheum Dis</source><volume>69</volume><issue>9</issue><year>2010</year><fpage>1629</fpage><lpage>1635</lpage><pub-id pub-id-type="pmid">20488885</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Mease</surname><given-names>P.J.</given-names></name><name><surname>Cohen</surname><given-names>S.</given-names></name><name><surname>Gaylis</surname><given-names>N.B.</given-names></name></person-group><article-title>Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE Trial</article-title><source>J Rheumatol</source><volume>37</volume><issue>5</issue><year>2010</year><fpage>917</fpage><lpage>927</lpage><pub-id pub-id-type="pmid">20194448</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>van Vollenhoven</surname><given-names>R.F.</given-names></name><name><surname>Fleischmann</surname><given-names>R.M.</given-names></name><name><surname>Furst</surname><given-names>D.E.</given-names></name><name><surname>Lacey</surname><given-names>S.</given-names></name><name><surname>Lehane</surname><given-names>P.B.</given-names></name></person-group><article-title>Longterm safety of rituximab: final report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 years</article-title><source>J Rheumatol</source><volume>42</volume><issue>10</issue><year>2015</year><fpage>1761</fpage><lpage>1766</lpage><pub-id pub-id-type="pmid">26276965</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Winthrop</surname><given-names>K.L.</given-names></name><name><surname>Saag</surname><given-names>K.</given-names></name><name><surname>Cascino</surname><given-names>M.D.</given-names></name></person-group><article-title>Long-term safety of rituximab in patients with rheumatoid arthritis: results of a five-year observational study</article-title><source>Arthritis Care Res (Hoboken)</source><volume>71</volume><issue>8</issue><year>2019</year><fpage>993</fpage><lpage>1003</lpage></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Joly</surname><given-names>P.</given-names></name><name><surname>Maho-Vaillant</surname><given-names>M.</given-names></name><name><surname>Prost-Squarcioni</surname><given-names>C.</given-names></name></person-group><article-title>First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial</article-title><source>Lancet</source><volume>389</volume><issue>10083</issue><year>2017</year><fpage>2031</fpage><lpage>2040</lpage><pub-id pub-id-type="pmid">28342637</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>N.</given-names></name><name><surname>Davies</surname><given-names>E.G.</given-names></name><name><surname>Thrasher</surname><given-names>A.J.</given-names></name></person-group><article-title>Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin</article-title><source>Br J Haematol</source><volume>146</volume><issue>1</issue><year>2009</year><fpage>120</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">19438506</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name><surname>Casulo</surname><given-names>C.</given-names></name><name><surname>Maragulia</surname><given-names>J.</given-names></name><name><surname>Zelenetz</surname><given-names>A.D.</given-names></name></person-group><article-title>Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections</article-title><source>Clin Lymphoma Myeloma Leuk</source><volume>13</volume><issue>2</issue><year>2013</year><fpage>106</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">23276889</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name><surname>Makatsori</surname><given-names>M.</given-names></name><name><surname>Kiani-Alikhan</surname><given-names>S.</given-names></name><name><surname>Manson</surname><given-names>A.L.</given-names></name></person-group><article-title>Hypogammaglobulinaemia after rituximab treatment&#x02014;incidence and outcomes</article-title><source>QJM</source><volume>107</volume><issue>10</issue><year>2014</year><fpage>821</fpage><lpage>828</lpage><pub-id pub-id-type="pmid">24778295</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name><surname>van Assen</surname><given-names>S.</given-names></name><name><surname>Holvast</surname><given-names>A.</given-names></name><name><surname>Benne</surname><given-names>C.A.</given-names></name></person-group><article-title>Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab</article-title><source>Arthritis Rheum</source><volume>62</volume><issue>1</issue><year>2010</year><fpage>75</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">20039396</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name><surname>Nazi</surname><given-names>I.</given-names></name><name><surname>Kelton</surname><given-names>J.G.</given-names></name><name><surname>Larch&#x000e9;</surname><given-names>M.</given-names></name></person-group><article-title>The effect of rituximab on vaccine responses in patients with immune thrombocytopenia</article-title><source>Blood</source><volume>122</volume><issue>11</issue><year>2013</year><fpage>1946</fpage><lpage>1953</lpage><pub-id pub-id-type="pmid">23851398</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name><surname>Eichenfield</surname><given-names>L.F.</given-names></name><name><surname>Bieber</surname><given-names>T.</given-names></name><name><surname>Beck</surname><given-names>L.A.</given-names></name></person-group><article-title>Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis</article-title><source>Am J Clin Dermatol</source><volume>20</volume><issue>3</issue><year>2019</year><fpage>443</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">31066001</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name><surname>Haberman</surname><given-names>R.</given-names></name><name><surname>Axelrad</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>A.</given-names></name></person-group><article-title>Covid-19 in immune-mediated inflammatory diseases&#x02014;case series from New York [e-pub ahead of print]</article-title><source>N Engl J Med</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMc2009567</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name><surname>Gianfrancesco</surname><given-names>M.A.</given-names></name><name><surname>Hyrich</surname><given-names>K.L.</given-names></name><name><surname>Gossec</surname><given-names>L.</given-names></name></person-group><article-title>Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries</article-title><source>Lancet Rheumatol</source><volume>2</volume><issue>5</issue><year>2020</year><fpage>e250</fpage><lpage>e253</lpage><pub-id pub-id-type="pmid">32309814</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>E.J.</given-names></name><name><surname>Ungaro</surname><given-names>R.C.</given-names></name><name><surname>Gearry</surname><given-names>R.B.</given-names></name></person-group><article-title>Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry [e-pub ahead of print]</article-title><source>Gastroenterology</source><year>2020</year><pub-id pub-id-type="doi">10.1053/j.gastro.2020.05.032</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name><surname>Damiani</surname><given-names>G.</given-names></name><name><surname>Pacifico</surname><given-names>A.</given-names></name><name><surname>Bragazzi</surname><given-names>N.L.</given-names></name><name><surname>Malagoli</surname><given-names>P.</given-names></name></person-group><article-title>Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during red-zone declaration [e-pub ahead of print]</article-title><source>Dermatol Ther</source><year>2020</year><pub-id pub-id-type="doi">10.1111/dth.13475</pub-id></element-citation></ref></ref-list><fn-group><fn id="d33e1118"><p id="ntpara0010">Drs Rosenbach and Merola contributed equally to the manuscript development (cosenior authors).</p></fn><fn id="d33e1121"><p id="ntpara0015">Funding sources: None.</p></fn><fn id="d33e1124"><p id="ntpara0020">Conflicts of interest: Dr Niaki has participated in an advisory board&#x000a0;for Eli Lilly. Dr Anadkat is currently serving as consultant for Boehringer-Ingelheim, NovoCure, and OnQuality and as&#x000a0;an&#x000a0;investigator for Biogen, Lutris, AnaptyxBio, Boehringer-Ingelheim, OnQuality, Norvartis, ChemoCentryx, UCB Biopharma, and XBiotech. Dr Shinohara has been a principle investigator for clinical trials (Actelion, Soligenix, MiRAGEN). Dr Rosenbach, has served as a consultant for Merck, aTyr, Processa, and Janssen and has received research support from <funding-source id="gs1">Processa</funding-source> and salary support from <italic>JAMA Dermatology</italic>. Dr Merola is a consultant and/or investigator for Merck, Bristol-Myers Squibb, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Celgene, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and LEO Pharma. Drs Chen, Fox, Harp, Micheletti, Nambudiri, and Pasieka have no conflicts of interest to declare.</p></fn><fn id="d33e1132"><p id="ntpara0025">IRB approval status: Not required.</p></fn><fn id="d33e1135"><p id="ntpara0075">Reprints not available from the authors.</p></fn></fn-group></back></article>